Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

• Market Cap: HK$1.11B
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: -4.88%
• EPS Growth: -34.75%
• Country: HK
• Employees: 260
• Sector: Basic Materials
• Sector Strength: 75
• Industry: Agricultural Inputs
• EPS (TTM): -0.01
• Shares Outstanding: 1,436,400,000
• 10 Day Avg. Volume: 2,806,000
• 30 Day Avg. Volume: 1,309,333
• PEG Ratio: 0.31
• Price to Book (P/B): 4.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: HK$0.50 ▲(0.00%Upside)

The primary concern is the company's weak financial performance, with high leverage and negative cash flow posing significant risks. Technically, the stock appears overbought, suggesting caution. The current valuation shows no profitability and no dividend yield, reducing its appeal as an investment.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) is a company engaged in the biomedical sector, focusing on the research, development, and commercialization of biotechnology products. The company primarily operates within the fields of medical and health products, offering a range of services and products designed to improve healthcare outcomes.

How the Company Makes Money

Tianjin TEDA Biomedical Engineering Co. Ltd. primarily generates revenue through the sale of its biotechnology products and services. The company's key revenue streams include the production and distribution of medical and health-related products, which are sold to healthcare providers and consumers. Additionally, the company may engage in partnerships or collaborations with other entities in the biomedical field, enhancing its market reach and product development capabilities. Revenue is also likely earned through licensing agreements and intellectual property related to its research and development efforts.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

Tianjin TEDA Biomedical Engineering Co. Ltd. is experiencing significant financial instability. The income statement highlights a declining revenue trend and consistent net losses. The balance sheet reveals a high Debt-to-Equity ratio, indicating heavy reliance on debt. Cash flow issues are evident with consistently negative operating cash flow, underscoring liquidity challenges.

Income Statement

The income statement reveals a declining trend in revenue, with Total Revenue decreasing from 476 million in 2021 to 385 million in 2024. Gross Profit Margin has narrowed significantly, and the company has been consistently incurring net losses, with a Net Income of -27.8 million in 2024. The EBIT and EBITDA margins are negative, indicating operational inefficiencies and challenges in maintaining profitability.

Balance Sheet

The balance sheet shows a weak financial structure with a high Debt-to-Equity ratio, increasing from 0.38 in 2019 to 7.22 in 2024, indicating heavy reliance on debt financing. Stockholders' Equity has diminished substantially, impacting the Equity Ratio, which fell to 6.66% in 2024. The company’s high leverage poses significant financial risk.

Cash Flow

Cash flow analysis points to severe issues, with Operating Cash Flow consistently negative, signaling poor cash generation ability. Free Cash Flow has been negative over multiple years, showing challenges in maintaining liquidity. The lack of positive cash flow ratios suggests difficulties in converting profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	423.65M	385.48M	398.00M	449.68M	476.38M	369.36M
Gross Profit	26.63M	16.97M	21.37M	16.40M	45.60M	40.39M
EBITDA	5.77M	-20.19M	4.79M	-2.26M	-29.86M	-14.65M
Net Income	-13.03M	-27.80M	-20.16M	-26.65M	-44.78M	-50.36M
Balance Sheet
Total Assets	310.05M	332.53M	303.28M	337.20M	347.60M	392.92M
Cash, Cash Equivalents and Short-Term Investments	92.73M	25.40M	5.93M	9.55M	29.78M	35.53M
Total Debt	110.53M	159.92M	83.56M	96.01M	90.34M	54.65M
Total Liabilities	251.00M	304.09M	238.70M	253.48M	237.24M	237.77M
Stockholders Equity	45.83M	22.15M	49.95M	72.67M	100.78M	143.04M
Cash Flow
Free Cash Flow	7.30M	0.00	-15.62M	-21.62M	-40.38M	21.96M
Operating Cash Flow	8.04M	0.00	-13.15M	-12.82M	-6.68M	35.99M
Investing Cash Flow	-748.74K	0.00	-467.44K	-12.93M	-8.51M	-26.51M
Financing Cash Flow	4.97M	0.00	12.73M	6.17M	28.10M	-20.19M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Positive. The current price of 0.5 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.42, and above the 200-day MA of 0.36, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 82.02 is Negative, neither overbought nor oversold. The STOCH value of 72.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0297	80 Outperform	$9.76B	8.49	10.52%	4.11%	-4.50%	58.32%
1866	79 Outperform	HK$7.04B	4.22	17.58%	5.00%	-3.45%	20.63%
3983	73 Outperform	HK$9.59B	8.25	5.83%	6.33%	-9.71%	-56.34%
Sector *	58 Neutral	HK$16.37B	4.50	-5.52%	4.91%	-3.57%	-61.41%
8189	40 Underperform	HK$1.11B	―	-81.86%	―	-4.88%	-34.75%
0827	35 Underperform	HK$150.70M	―	-76.72%	―	-12.18%	-222.34%